Showing results (11-20 of 20) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Respiratory Investigation|June 19, 2021
Apalutamide-induced severe interstitial lung disease: A report of two cases from JapanHiroshi Kobe, Ryo Tachikawa, Yoshitsugu Masuno, et al.Cureus|July 3, 2024
Diagnostic Usefulness of Liquid Culture Medium for Mycobacterium avium-intracellulare Complex Lung Disease: A Single-Centre, Retrospective StudyHiroshi Kobe, Akihiro Ito, Yosuke Nakanishi, et al.Journal of Cancer Research and Clinical Oncology|June 23, 2022
Efficacy and safety of immuno-chemotherapy in patients with advanced non-small-cell lung cancer harboring oncogenic mutations: a multicenter retrospective studyTae Hata, Chikara Sakaguchi, Keita Hirano, et al.Thoracic Cancer|March 3, 2023
Exploratory analysis of immunochemotherapy compared to chemotherapy after EGFR-TKI in non-small cell lung cancer patients with EGFR mutation: A multicenter retrospective studyTae Hata, Chikara Sakaguchi, Keita Hirano, et al.JTO Clinical and Research Reports|June 30, 2022
Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort StudyHayato Kawachi, Motohiro Tamiya, Yoshihiko Taniguchi, et al.Journal of Cancer Research and Clinical Oncology|October 29, 2022
More than one-third of advanced non-small-cell lung cancer patients do not receive immunochemotherapy due to intoleranceChihiro Ando, Eiki Ichihara, Toshihide Yokoyama, et al.Cancer Medicine|November 10, 2023
Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single-plex testing: WJOG13620LTakehiro Uemura, Hirotsugu Kenmotsu, Daisuke Hazama, et al.European Journal of Cancer (Oxford, England : 1990)|November 8, 2021
Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT)Yoshihiko Sakata, Shinya Sakata, Yuko Oya, et al.European Journal of Cancer (Oxford, England : 1990)|December 5, 2022
Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort studyMihoko Imaji, Daichi Fujimoto, Yuki Sato, et al.Chest|June 6, 2022
Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Real-World SettingYuki Sato, Hiromitsu Sumikawa, Ryota Shibaki, et al.Pageof 2